Inventiva is developing lanifibranor, an oral pan-PPAR agonist aimed at treating MASH (metabolic dysfunction-associated steatohepatitis). The drug offers dual metabolic and anti-fibrotic benefits and is seen as complementary to existing treatments like GLP-1 and SGLT2 agents. Inventiva has secured enough funding through mid-2027 and improved governance ahead of the pivotal NATiV3 Phase 3 trial results expected in Q4 2026. Success in this trial could establish lanifibranor as a versatile and differentiated option in the evolving MASH treatment landscape.
Capitan Silver Corp. announced its participation in the first Gentile Mining Investor Forum on October 19, 2026, in London. The event gathers investors and mining companies for one-on-one meetings and showcases, providing Capitan an opportunity to pr...
Solana's SOL token surged past $116, causing a major short squeeze that liquidated over $18 million in bearish positions. This rally began after SOL broke through the $110 resistance level for the first time in seven months, forcing short sellers to ...
Shares of Critical Metals surged 25% following a U.S.-Greenland security pact that highlighted the company's Tanbreez rare earth exploitation permit in Greenland. The pact grants the U.S. permanent security control in Greenland but does not change mi...
AMD's stock surged 254% in the past year, driven by triple-digit growth in its Data Center segment, which now makes up 58% of revenue. Despite this, the 24/7 Wall St. price target is $510.66, below the current $559.82 price, reflecting concerns about...
Meta Platforms faces a $10 billion legal charge from an $18 billion settlement affecting its near-term earnings, but its core business remains strong and cash flow covers obligations comfortably. The company is diversifying revenue through new launch...
